Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

Effects of central and peripheral cueing on perceptual and saccade performance.

Moehler T, Fiehler K.

Vision Res. 2018 Feb;143:26-33. doi: 10.1016/j.visres.2017.12.002. Epub 2017 Dec 22.

2.

Inhibition in movement plan competition: reach trajectories curve away from remembered and task-irrelevant present but not from task-irrelevant past visual stimuli.

Moehler T, Fiehler K.

Exp Brain Res. 2017 Nov;235(11):3251-3260. doi: 10.1007/s00221-017-5051-z. Epub 2017 Aug 1.

PMID:
28765992
3.

Diagnostic and therapeutic approaches to multiple myeloma patients: 'Real-world' data from representative multicentre treatment surveys in Germany between 2008 and 2011.

Moehler TM, Merz M, Kellermann L, Goldschmidt H, Knauf W.

Oncol Lett. 2016 Dec;12(6):5043-5051. doi: 10.3892/ol.2016.5375. Epub 2016 Nov 10.

4.

Increased microcirculation detected by dynamic contrast-enhanced magnetic resonance imaging is of prognostic significance in asymptomatic myeloma.

Hillengass J, Ritsch J, Merz M, Wagner B, Kunz C, Hielscher T, Laue H, Bäuerle T, Zechmann CM, Ho AD, Schlemmer HP, Goldschmidt H, Moehler TM, Delorme S.

Br J Haematol. 2016 Jul;174(1):127-35. doi: 10.1111/bjh.14038. Epub 2016 Mar 15.

PMID:
26991959
5.

A Furan-Based Lewis-Y-(CD174)-Saccharide Mimetic Inhibits Endothelial Functions and In Vitro Angiogenesis.

Sauer S, Meissner T, Moehler T.

Adv Clin Exp Med. 2015 Sep-Oct;24(5):759-68. doi: 10.17219/acem/38562.

6.

The influence of spatial congruency and movement preparation time on saccade curvature in simultaneous and sequential dual-tasks.

Moehler T, Fiehler K.

Vision Res. 2015 Nov;116(Pt A):25-35. doi: 10.1016/j.visres.2015.09.006. Epub 2015 Sep 29.

7.

Prognostic significance of increased bone marrow microcirculation in newly diagnosed multiple myeloma: results of a prospective DCE-MRI study.

Merz M, Moehler TM, Ritsch J, Bäuerle T, Zechmann CM, Wagner B, Jauch A, Hose D, Kunz C, Hielscher T, Laue H, Goldschmidt H, Delorme S, Hillengass J.

Eur Radiol. 2016 May;26(5):1404-11. doi: 10.1007/s00330-015-3928-4. Epub 2015 Jul 29.

PMID:
26215436
8.
9.

The application of Gadopentate-Dimeneglumin has no impact on progression free and overall survival as well as renal function in patients with monoclonal plasma cell disorders if general precautions are taken.

Hillengass J, Stoll J, Zechmann CM, Kunz C, Wagner B, Heiss C, Sumkauskaite M, Moehler TM, Schlemmer HP, Goldschmidt H, Delorme S.

Eur Radiol. 2015 Mar;25(3):745-50. doi: 10.1007/s00330-014-3458-5. Epub 2014 Oct 31.

PMID:
25358594
10.

Dynamic contrast-enhanced magnetic resonance imaging for assessment of antiangiogenic treatment effects in multiple myeloma.

Merz M, Ritsch J, Kunz C, Wagner B, Sauer S, Hose D, Moehler T, Delorme S, Goldschmidt H, Zechmann C, Hillengass J.

Clin Cancer Res. 2015 Jan 1;21(1):106-12. doi: 10.1158/1078-0432.CCR-14-1029. Epub 2014 Oct 28.

11.

The glycome of normal and malignant plasma cells.

Moehler TM, Seckinger A, Hose D, Andrulis M, Moreaux J, Hielscher T, Willhauck-Fleckenstein M, Merling A, Bertsch U, Jauch A, Goldschmidt H, Klein B, Schwartz-Albiez R.

PLoS One. 2013 Dec 26;8(12):e83719. doi: 10.1371/journal.pone.0083719. eCollection 2013.

12.

Treatment with Thalidomide and Cyclophosphamide (TCID) is Superior to Vincristine (VID) and to Vinorelbine (VRID) Regimens in Patients with Refractory or Recurrent Multiple Myeloma.

Auel B, Goldschmidt H, Geer T, Moehler TM, Platzbecker U, Naumann R, Blau I, Hänel M, Knauf W, Nückel H, Salwender HJ, Scheid C, Weisel K, Gorschlüter M, Glasmacher A, Schmidt-Wolf IG; German Refractory Myeloma Study Group.

Indian J Hematol Blood Transfus. 2012 Jun;28(2):67-76. doi: 10.1007/s12288-011-0103-1. Epub 2011 Aug 18.

13.

Bisphosphonate treatment and renal function in 201 myeloma patients undergoing stem cell transplantation.

Schmitt S, Hielscher T, Baldus C, Neben K, Egerer G, Hillengaß J, Raab M, Hose D, Ho AD, Bergner R, Goldschmidt H, Moehler TM.

Int J Hematol. 2013 Jun;97(6):765-72. doi: 10.1007/s12185-013-1320-1. Epub 2013 Apr 25.

PMID:
23616219
14.

Sorafenib in patients with refractory or recurrent multiple myeloma.

Yordanova A, Hose D, Neben K, Witzens-Harig M, Gütgemann I, Raab MS, Moehler T, Goldschmidt H, Schmidt-Wolf IG.

Hematol Oncol. 2013 Dec;31(4):197-200. doi: 10.1002/hon.2043. Epub 2013 Mar 15.

PMID:
23494836
15.

Clinical experience with thalidomide and lenalidomide in multiple myeloma.

Moehler T.

Curr Cancer Drug Targets. 2012 May;12(4):372-90. Review.

PMID:
22229246
16.

Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial.

Kropff M, Baylon HG, Hillengass J, Robak T, Hajek R, Liebisch P, Goranov S, Hulin C, Bladé J, Caravita T, Avet-Loiseau H, Moehler TM, Pattou C, Lucy L, Kueenburg E, Glasmacher A, Zerbib R, Facon T.

Haematologica. 2012 May;97(5):784-91. doi: 10.3324/haematol.2011.044271. Epub 2011 Dec 1.

17.

Therapy of relapsed and refractory multiple myeloma.

Moehler T, Goldschmidt H.

Recent Results Cancer Res. 2011;183:239-71. doi: 10.1007/978-3-540-85772-3_11. Review.

PMID:
21509688
18.

Monoclonal gammopathy and smoldering multiple myeloma: diagnosis, staging, prognosis, management.

Hillengass J, Moehler T, Hundemer M.

Recent Results Cancer Res. 2011;183:113-31. doi: 10.1007/978-3-540-85772-3_6. Review.

PMID:
21509683
19.

Molecular pathogenesis of multiple myeloma: chromosomal aberrations, changes in gene expression, cytokine networks, and the bone marrow microenvironment.

Klein B, Seckinger A, Moehler T, Hose D.

Recent Results Cancer Res. 2011;183:39-86. doi: 10.1007/978-3-540-85772-3_3. Review.

PMID:
21509680
20.

Combined phase I/II study of imexon (AOP99.0001) for treatment of relapsed or refractory multiple myeloma.

Moehler TM, Feneberg R, Ho AD, Golenkov AK, Ludwig H, Kropff M, Khuageva NK, Hajda J, von Broen I, Goldschmidt H.

Anticancer Drugs. 2010 Aug;21(7):708-15. doi: 10.1097/CAD.0b013e32833b975b.

PMID:
20571355
21.

Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma.

Hillengass J, Fechtner K, Weber MA, Bäuerle T, Ayyaz S, Heiss C, Hielscher T, Moehler TM, Egerer G, Neben K, Ho AD, Kauczor HU, Delorme S, Goldschmidt H.

J Clin Oncol. 2010 Mar 20;28(9):1606-10. doi: 10.1200/JCO.2009.25.5356. Epub 2010 Feb 22.

PMID:
20177023
22.

Transcriptional regulation of the vascular endothelial glycome by angiogenic and inflammatory signalling.

Willhauck-Fleckenstein M, Moehler TM, Merling A, Pusunc S, Goldschmidt H, Schwartz-Albiez R.

Angiogenesis. 2010 Mar;13(1):25-42. doi: 10.1007/s10456-010-9162-4. Epub 2010 Feb 17.

PMID:
20162350
23.

Multiple myeloma and monoclonal gammopathy of undetermined significance: importance of whole-body versus spinal MR imaging.

Bäuerle T, Hillengass J, Fechtner K, Zechmann CM, Grenacher L, Moehler TM, Christiane H, Wagner-Gund B, Neben K, Kauczor HU, Goldschmidt H, Delorme S.

Radiology. 2009 Aug;252(2):477-85. doi: 10.1148/radiol.2522081756.

PMID:
19703885
24.

Dynamic contrast-enhanced magnetic resonance imaging identifies a subgroup of patients with asymptomatic monoclonal plasma cell disease and pathologic microcirculation.

Hillengass J, Zechmann C, Bäuerle T, Wagner-Gund B, Heiss C, Benner A, Ho A, Neben K, Hose D, Kauczor HU, Goldschmidt H, Delorme S, Moehler T.

Clin Cancer Res. 2009 May 1;15(9):3118-25. doi: 10.1158/1078-0432.CCR-08-2310. Epub 2009 Apr 14.

25.

Clinical evidence for immunomodulation induced by high-dose melphalan and autologous blood stem cell transplantation as cause for complete clinical remission of multiple myeloma-associated cryoglobulin-vasculitis.

Hillengass J, Ho AD, Goldschmidt H, Waldherr R, Moehler TM.

Int J Hematol. 2008 Nov;88(4):454-456. doi: 10.1007/s12185-008-0177-1. Epub 2008 Oct 11.

PMID:
18846323
26.

Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone.

Klein U, Kosely F, Hillengass J, Hundemer M, Schmitt S, Neben K, Moehler T, Hegenbart U, Ho AD, Goldschmidt H.

Ann Hematol. 2009 Jan;88(1):67-71. doi: 10.1007/s00277-008-0561-1. Epub 2008 Jul 31.

PMID:
18668241
27.

Gain of 1q21 and distinct adverse cytogenetic abnormalities correlate with increased microcirculation in multiple myeloma.

Hillengass J, Zechmann CM, Nadler A, Hose D, Cremer FW, Jauch A, Heiss C, Benner A, Ho AD, Bartram CR, Kauczor HU, Delorme S, Goldschmidt H, Moehler TM.

Int J Cancer. 2008 Jun 15;122(12):2871-5. doi: 10.1002/ijc.23455.

28.

Successful autologous peripheral blood stem cell transplantation in a Jehovah's Witness with multiple myeloma: review of literature and recommendations for high-dose chemotherapy without support of allogeneic blood products.

Schmitt S, Mailaender V, Egerer G, Leo A, Becker S, Reinhardt P, Wiesneth M, Schrezenmeier H, Ho AD, Goldschmidt H, Moehler TM.

Int J Hematol. 2008 Apr;87(3):289-97. doi: 10.1007/s12185-008-0055-x. Epub 2008 Mar 4. Review.

PMID:
18317881
29.

Involvement of alpha 1-2-fucosyltransferase I (FUT1) and surface-expressed Lewis(y) (CD174) in first endothelial cell-cell contacts during angiogenesis.

Moehler TM, Sauer S, Witzel M, Andrulis M, Garcia-Vallejo JJ, Grobholz R, Willhauck-Fleckenstein M, Greiner A, Goldschmidt H, Schwartz-Albiez R.

J Cell Physiol. 2008 Apr;215(1):27-36. doi: 10.1002/jcp.21285.

PMID:
18205178
30.

Where is the primary tumour?

Zechmann CM, Giesel FL, Hillengass J, Mehndiratta A, Neben K, Delorme S, Moehler T.

Lancet. 2007 Nov 24;370(9601):1800. No abstract available.

PMID:
18037083
31.

Long-term remission of paraprotein-induced immunotactoid glomerulopathy after high-dose therapy and autologous blood stem cell transplantation.

Witzens-Harig M, Waldherr R, Beimler J, Zeier M, Hansmann J, Ho AD, Goldschmidt H, Moehler T.

Ann Hematol. 2007 Dec;86(12):927-30. Epub 2007 Jun 29. No abstract available.

PMID:
17605010
32.

Efficient mobilization of peripheral blood stem cells following CAD chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma.

Fruehauf S, Klaus J, Huesing J, Veldwijk MR, Buss EC, Topaly J, Seeger T, Zeller LW, Moehler T, Ho AD, Goldschmidt H.

Bone Marrow Transplant. 2007 Jun;39(12):743-50. Epub 2007 Apr 23.

PMID:
17450182
33.

Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma.

Mahtouk K, Hose D, Raynaud P, Hundemer M, Jourdan M, Jourdan E, Pantesco V, Baudard M, De Vos J, Larroque M, Moehler T, Rossi JF, Rème T, Goldschmidt H, Klein B.

Blood. 2007 Jun 1;109(11):4914-23. Epub 2007 Mar 5.

34.

Cancer/testis genes in multiple myeloma: expression patterns and prognosis value determined by microarray analysis.

Condomines M, Hose D, Raynaud P, Hundemer M, De Vos J, Baudard M, Moehler T, Pantesco V, Moos M, Schved JF, Rossi JF, Rème T, Goldschmidt H, Klein B.

J Immunol. 2007 Mar 1;178(5):3307-15.

35.

Lumbar bone marrow microcirculation measurements from dynamic contrast-enhanced magnetic resonance imaging is a predictor of event-free survival in progressive multiple myeloma.

Hillengass J, Wasser K, Delorme S, Kiessling F, Zechmann C, Benner A, Kauczor HU, Ho AD, Goldschmidt H, Moehler TM.

Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):475-81.

36.

Thalidomide in multiple myeloma.

Moehler TM, Hillengass J, Glasmacher A, Goldschmidt H.

Curr Pharm Biotechnol. 2006 Dec;7(6):431-40. Review.

PMID:
17168659
37.

The outcome of autologous stem cell transplantation in patients with plasma cell disorders and dialysis-dependent renal failure.

Raab MS, Breitkreutz I, Hundemer M, Benner A, Klaus J, Hegenbart U, Moehler T, Ho AD, Zeier M, Goldschmidt H.

Haematologica. 2006 Nov;91(11):1555-8.

38.

Effect of CD34 cell dose on hematopoietic reconstitution and outcome in 508 patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation.

Klaus J, Herrmann D, Breitkreutz I, Hegenbart U, Mazitschek U, Egerer G, Cremer FW, Lowenthal RM, Huesing J, Fruehauf S, Moehler T, Ho AD, Goldschmidt H.

Eur J Haematol. 2007 Jan;78(1):21-8. Epub 2006 Sep 28.

PMID:
17042762
39.

Preoperative elevation of serum C--reactive protein is predictive for prognosis in myeloma bone disease after surgery.

Zahlten-Hinguranage A, Goldschmidt H, Cremer FW, Egerer G, Moehler T, Witte D, Bernd L, Sabo D, Zeifang F.

Br J Cancer. 2006 Oct 9;95(7):782-7. Epub 2006 Sep 12.

41.

Chromosomal aberrations in 130 patients with multiple myeloma studied by interphase FISH: diagnostic and prognostic relevance.

Schmidt-Wolf IG, Glasmacher A, Hahn-Ast C, Jüttner A, Schnurr T, Cremer F, Moehler T, Goldschmidt H, Busert B, Schubert R, Schwanitz G.

Cancer Genet Cytogenet. 2006 May;167(1):20-5.

PMID:
16682281
42.

Endovenous treatment of the great saphenous vein using a 1,320 nm Nd:YAG laser causes fewer side effects than using a 940 nm diode laser.

Proebstle TM, Moehler T, Gül D, Herdemann S.

Dermatol Surg. 2005 Dec;31(12):1678-83; discussion 1683-4.

PMID:
16336887
43.

[Correlation of MRI and histopathology of bone marrow in patients with multiple myeloma].

Wasser K, Moehler T, Nosas-Garcia S, Rehm C, Bartl R, Goldschmidt H, Düber C, Kauczor HU, Delorme S.

Rofo. 2005 Aug;177(8):1116-22. German.

PMID:
16021544
44.

Dynamic contrast-enhanced MRI for assessing the disease activity of multiple myeloma: a comparative study with histology and clinical markers.

Nosàs-Garcia S, Moehler T, Wasser K, Kiessling F, Bartl R, Zuna I, Hillengass J, Goldschmidt H, Kauczor HU, Delorme S.

J Magn Reson Imaging. 2005 Jul;22(1):154-62.

PMID:
15971177
45.

Combined effect of recombinant CD19 x CD16 diabody and thalidomide in a preclinical model of human B cell lymphoma.

Schlenzka J, Moehler TM, Kipriyanov SM, Kornacker M, Benner A, Bähre A, Stassar MJ, Schäfer HJ, Little M, Goldschmidt H, Cochlovius B.

Anticancer Drugs. 2004 Oct;15(9):915-9.

PMID:
15457133
46.

[Dynamic MRI of the bone marrow for monitoring multiple myeloma during treatment with thalidomide as monotherapy or in combination with CED chemotherapy].

Wasser K, Moehler T, Neben K, Nosas S, Heiss J, Goldschmidt H, Hillengass J, Düber C, Kauczor HU, Delorme S.

Rofo. 2004 Sep;176(9):1285-95. German.

PMID:
15346264
47.

Antiangiogenic therapy in hematologic malignancies.

Moehler TM, Hillengass J, Goldschmidt H, Ho AD.

Curr Pharm Des. 2004;10(11):1221-34. Review.

PMID:
15078137
48.

Combination therapy of Thalidomide and Peginterferon in patients with progressive multiple myeloma.

Kasper B, Moehler T, Neben K, Ho AD, Goldschmidt H.

Ann Oncol. 2004 Jan;15(1):176-7. No abstract available.

PMID:
14679142
49.

Development of leukocytoclastic vasculitis in a patient with multiple myeloma during treatment with thalidomide.

Witzens M, Moehler T, Neben K, Fruehauf S, Hartschuh W, Ho AD, Goldschmidt H.

Ann Hematol. 2004 Jul;83(7):467-70. Epub 2003 Nov 19.

PMID:
14625789
50.

Lack of evidence for inhibition of angiogenesis as a central mechanism of the antiarthritic effect of methotrexate.

Fiehn C, Wunder A, Krienke S, Max R, Ho AD, Moehler T.

Rheumatol Int. 2005 Mar;25(2):108-13. Epub 2003 Nov 15.

PMID:
14618373

Supplemental Content

Loading ...
Support Center